EMD Millipore offers a range of performance products, services and business relationships that enable customers’ success in research, development and production of biotech and pharmaceutical drug therapies.
With this acquisition, Amnis will expand its growth potential via EMD Millipore’s global footprint, reagent expertise, and R&D resources.
Further, the acquisition will also complement EMD Millipore’s Guava flow cytometry product range.
Amnis CEO David Basiji said the combination of Amnis with EMD Millipore will accelerate development of novel applications in imaging flow cytometry, enhance their customer support, and accelerate product development.